Abstract / Description of output
Background and aims: My Diabetes My Way (MDMW) is Scotland’s interactive
website and mobile app for people with diabetes and their caregivers. It contains
multimedia resources for diabetes education and offers access to electronic personal health records. This study aims to assess the cost-utility of MDMW compared to routine diabetes care in people with type 2 diabetes who do not use insulin.
Materials and methods: Analysis used the United Kingdom Prospective Diabetes
Study (UKPDS) Outcomes Model2. Clinical parameters of MDMW users (n=2,576) were compared with a matched cohort of individuals receiving routine care alone (n=11,628).
Matching criteria: age, diabetes duration, sex and socio-economic status. Impact on life expectancy, quality-adjusted life years (QALYs) and costs of treatment and
complications were simulated over ten years, including a 10% sensitivity analysis.
Results: MDMW cohort: 1,670 (64.8%) men; average age 64.3 years; duration of
diabetes 5.5 years. 906 (35.2%) women: average age 61.6; duration 4.7 years. The
cumulative mean QALY (95% CI) gain: 0.054 (0.044; 0.062) years. Mean difference in cost: -£118.72 (-£150.16; -£54.16) over ten years. Increasing MDMW costs (10%): - £50.49 (-£82.24; £14.14). Decreasing MDMW costs (10%): -£186.95 (-£218.53; - £122.51).
Conclusions: MDMW is ‘dominant’ over usual care (cost-saving and life improving) in supporting self-management in people with type 2 diabetes not treated with insulin. Wider use may result in significant cost savings through delay or reduction of long-term complications and improved QALYs in Scotland and other countries. MDMW may be among the most cost-effective interventions currently available to support diabetes.
website and mobile app for people with diabetes and their caregivers. It contains
multimedia resources for diabetes education and offers access to electronic personal health records. This study aims to assess the cost-utility of MDMW compared to routine diabetes care in people with type 2 diabetes who do not use insulin.
Materials and methods: Analysis used the United Kingdom Prospective Diabetes
Study (UKPDS) Outcomes Model2. Clinical parameters of MDMW users (n=2,576) were compared with a matched cohort of individuals receiving routine care alone (n=11,628).
Matching criteria: age, diabetes duration, sex and socio-economic status. Impact on life expectancy, quality-adjusted life years (QALYs) and costs of treatment and
complications were simulated over ten years, including a 10% sensitivity analysis.
Results: MDMW cohort: 1,670 (64.8%) men; average age 64.3 years; duration of
diabetes 5.5 years. 906 (35.2%) women: average age 61.6; duration 4.7 years. The
cumulative mean QALY (95% CI) gain: 0.054 (0.044; 0.062) years. Mean difference in cost: -£118.72 (-£150.16; -£54.16) over ten years. Increasing MDMW costs (10%): - £50.49 (-£82.24; £14.14). Decreasing MDMW costs (10%): -£186.95 (-£218.53; - £122.51).
Conclusions: MDMW is ‘dominant’ over usual care (cost-saving and life improving) in supporting self-management in people with type 2 diabetes not treated with insulin. Wider use may result in significant cost savings through delay or reduction of long-term complications and improved QALYs in Scotland and other countries. MDMW may be among the most cost-effective interventions currently available to support diabetes.
Original language | English |
---|---|
Journal | Journal of Diabetes Science and Technology |
Early online date | 5 Jan 2022 |
DOIs | |
Publication status | E-pub ahead of print - 5 Jan 2022 |
Keywords / Materials (for Non-textual outputs)
- eHealth
- education
- health care delivery
- health economics
- information technology
- medical informatics
- self-management